OTHER
Amylin (Pramlintide)
Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
Status
Completed
Phase
Not applicable
Enrollment
36
Locations
1
Results
Not posted
Publications
0
Study summary
Amylin and calcitonin gene related peptide (CGRP) are related to the same peptide family. Both share 16 out of 37 amino acids and can activate each others receptor. CGRP is implicated in migraine pathophysiology but the role of Amylin and its receptor in migraine is not fully clarified.
Amylin is a peptide hormone that binds to a G-protein coupled receptor (GPCR). amylin was originally found in the pancreas (Beta Cell of Islets of Langerhans) but also shown to be present in the trigeminal ganglion, hind horn ganglia and perivascular nerve fibers. Amylin has many similarities with CGRP. Amylin and CGRP share 16 out 37 amino acids. Both peptides can activate the amylin 1 subtype (AMY1)receptor with high affinity and reported to have more similar physiological and pharmacological effects. In addition, both peptides increase the intracellular concentration of cyclic AMP (cAMP) which has a central role in migraine pathophysiology. The aim of the study is pin point the role of amylin and amylin receptor compare to CGRP in migraine pathophysiology.
Interventions
OTHER
Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
OTHER
CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
Timeline
First posted
Jul 26, 2018
Study start
Jul 1, 2018
Primary completion
Sep 30, 2019
Study completion
Dec 31, 2019
Results posted
Not reported
Registry updated
Jun 25, 2020
Outcomes
Migraine incidence
Time frame · 12 hours
Before (-10 min) and after infusion (+12 hours) of amlyin compared with before and after infusion of CGRP based on questionnaire reported headache and associated symptoms
Dilatation of Arteria radialis and arteria temporalis superficialis
Time frame · 2 hours
Dermascan will be used to measure the above mentioned Radial and temporal arteries diameter.
Facial flushing
Time frame · 2 hours
Flushing will measured by laser contrast imaging
Plasma blood samples
Time frame · 2 hours
Measumrent of amylin and CGRP peptides in the plasma in picomol/L
Headache intensity
Time frame · 12 hours
Measured by visual analog score (VAS) ( 0 to 10). Change in area under curve (AUC)
Eligibility
Inclusion Criteria: * Migraine patients meeting International Headache Society (IHS) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg. * Fertile women should use safe contraception. Fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. Safe contraception includes either Intra Uterine Device (IUD), birth control pills, surgical sterilization of the woman or depot progestogen. Exclusion Criteria: * Tension Type headache for more than 5 days the month on average in the last year. * All other primary headaches . * Headache later than 48 hours before trial start. * Daily intake of any medicine other than oral contraception. * Ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception. * Pregnant or breastfeeding women. * Headache on the test day or later than 48 hours prior to administration of trial medicine / placebo * Migraine within 5 days before the trial date. * Ancestral information or clinical signs of (on the day of inclusion): * Hypertension (systolic blood pressure\> 150 mmHg and / or diastolic blood pressure\> 100 mmHg) * Hypotension (systolic blood pressure \<90 mm Hg and / or diastolic blood pressure \<50 mmHg) * Cardiovascular disease of all kinds, including cerebrovascular disease. * Anamnestic or clinical signs of mental illness or abuse. * Patients with glaucoma or prostatic hyperplasia * Anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.
Study locations
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Danish Headache Center
Glostrup Municipality, Denmark
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
University of Copenhagen · Healthy Adult Participants · Bone Physiology
Not applicable
Not yet recruiting
15
2026-07
Oregon Health and Science University · Type 1 Diabetes
Not applicable
Completed
33
2026-06
Boston University · Alzheimer Disease · Mild Cognitive Impairment
Early Phase 1
Active, not recruiting
57
2026-05
Esbjerg Hospital - University Hospital of Southern Denmark · Obesity · Appetite Regulation
Phase 2 / Phase 3
Withdrawn
0
2026-04
University Hospital, Gentofte, Copenhagen · Obesity & Overweight
Not applicable
Recruiting
18
2026-04
Danish Headache Center · Headache Disorders, Secondary · Brain Diseases
Not applicable
Not yet recruiting
21
2026-01
Danish Headache Center · Headache Disorders, Primary · Headache Disorders
Not applicable
Not yet recruiting
21
2026-01
McGill University Health Centre/Research Institute of the McGill University Health Centre · type1diabetes · Diabetes Mellitus, Type 1
Phase 2 / Phase 3
Unknown
30
2024-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.